FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation

Last updated: February 27, 2023
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Fabry Disease

Circulation Disorders

Kidney Disease

Treatment

N/A

Clinical Study ID

NCT05761834
4756
  • Ages 18-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

In Fabry disease (FD) and hypertrophic cardiomyopathy (HCM) systemic inflammation recently gained attention as a possible key pathophysiologic process involved in the development of cardiac hypertrophy and progression of the disease. Differences in inflammatory profile between FD and HCM have never been investigated so far.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years;
  • Patients with confirmed genetic diagnosis of FD19;
  • Patients with a known diagnosis of sarcomeric HCM adult (with pathogenic mutation insarcomeric genes identified);
  • Signed informed consent.

Exclusion

Exclusion Criteria:

  • Age <18 years;
  • Diagnosis of Autoinflammatory disorders;
  • History of recurrent infections;
  • HIV infection;
  • Active cancer;
  • History of organ transplantation needing chronic immunosuppressor treatment;
  • Pregnancy
  • Refusal to sign informed consent to study participation.

Study Design

Total Participants: 150
Study Start date:
January 27, 2023
Estimated Completion Date:
January 10, 2025

Study Description

This study investigate whether partecipants with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells. Moreover, the investigators sought to explore if a correlation exists between the inflammatory phenotype and the severity of cardiac phenotype cardiovascular events during 24 months of follow up.

This will be a prospective, multicenter, observational study. Adult partecipants with a genetically-proven diagnosis of FD and age-matched patients with a diagnosis of sarcomeric HCM will be enrolled, according to the following exclusion criteria:

  1. Diagnosis Autoinflammatory disorders;

  2. history of recurrent infections;

  3. HIV infection;

  4. Active cancer;

  5. History of organ transplantation needing chronic immunosuppressor treatment. For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin [IL]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor [TNF], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease [MMP]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein.

Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed. Partecipants enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram.

Connect with a study center

  • Fondazione Policlinico Gemelli

    Roma, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.